Skip to content
Open access

Valid Data‐Driven Subgroup Selection With Uniform Guarantees in Clinical Trials

Oct 2026 · Statistics in Medicine · Vol 45 · 0 citations · 62 references
Medicine

TL;DR

Two recently developed methods for subgroup selection in regression problems are discussed: one based on generalized linear modeling and another on isotonic regression, focusing on two distinct tasks: identifying patient groups that are safe from manifesting adverse events and identifying patient groups with high treatment effect, while controlling for Type I error in both cases.

Abstract

Subgroup selection in clinical trials is essential for identifying patient groups that react differently to a treatment, thereby enabling personalized medicine. In particular, subgroup selection can identify patient groups that respond particularly well to a treatment or that encounter adverse events more often. However, this is a post‐selection inference problem, which may pose challenges for traditional techniques used for subgroup analysis, such as increased Type I error rates and potential biases from data‐driven subgroup identification. In this paper, we discuss two recently developed methods for subgroup selection in regression problems: one based on generalized linear modeling and another on isotonic regression. We demonstrate how these methods can be used for data‐driven subgroup identification in the analysis of clinical trials, focusing on two distinct tasks: identifying patient groups that are safe from manifesting adverse events and identifying patient groups with high treatment effect, while controlling for Type I error in both cases. A thorough simulation study is conducted to evaluate the strengths and weaknesses of each method, providing detailed insight into the sensitivity of the Type I error rate control to modeling assumptions.

Read PDF

Similar papers

Open access Sep 2026

Population-Adjusted Survival: A Real-World, Epidemiologic Approach for Analyzing Time-to-Event Clinical Trial Data

Results of a clinical trial may misrepresent the target population. Inappropriate inclusion/exclusion criteria, selective recruitment, and differential participation may restrict the number of patients who consent to join the study. Frequently, they differ from the real-world population in terms of key outcome-related...

J. Efird, Genevieve N. Dupuis, Yuk-Ming Choi et al. · 0 citations
Open access Oct 2026

Multivariate Analysis of Data From Crossover Clinical Trials

In crossover designs, multiple outcomes are often collected to assess treatment effectiveness in a comprehensive manner. Also, interest has grown in comparing intra‐subject variability between treatments in such designs. We present three distinct multivariate linear mixed‐effects models, with the choice of the model de...

Yi Jiang, V. Chinchilli · 0 citations
Open access Oct 2026

Power With Confounders in Clinical Trials Using External Controls.

When the number of patients is limited in clinical trials for rare diseases and pediatric developments, enrolling sufficient participants for confirmatory randomized clinical trials is difficult. Alternative trial designs using external controls have been proposed: augmented randomized clinical trials (ARCTs) and suppl...

K. Kudo, Tosiya Sato · 0 citations
Review Oct 2026

Heterogeneity and Subgrouping in Modern Statistics and AI

A unified perspective in which heterogeneous analysis is a problem of structured information borrowing is developed, with an agenda for calibrated personalization that integrates multilevel representations, selective borrowing, subgroup-aware evaluation, and valid uncertainty quantification.

Xuan Bi, Spencer Hilligoss, C. Pinkerton et al. · 0 citations
Preprint Sep 2026

Inference for Standard Trial Estimands after Data-Driven Subgroup Discovery

Data-driven subgroup identification is increasingly used in clinical trials, yet the effect reported for a discovered subgroup is typically the standard analysis: a Cox or generalized-linear-model treatment coefficient fitted within that subgroup. Selection by an effect-driven rule --- rewarding large estimated effects...

Larry F. León, Keaven M. Anderson · 0 citations
Open access Sep 2026

A Neutral Comparison of Multivariate Hypothesis Tests for Parallel Group Designs in Rare Disease Settings

Multivariate endpoints are increasingly used in clinical studies on rare diseases, where sample sizes tend to be small and distributional assumptions are often violated. In such settings, commonly applied parametric multivariate methods, such as classical MANOVA approaches, may suffer from inflated type‐I error or redu...

Martin Geroldinger, M. Laimer, V. Wally et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.